| 胸腺五肽对新辅助化疗的乳腺癌患者局部组织中浸润淋巴细胞的影响 |
| 投稿时间：2016-12-05 修订日期：2017-01-01 点此下载全文 |
| 引用本文：郭瑛,王凯.胸腺五肽对新辅助化疗的乳腺癌患者局部组织中浸润淋巴细胞的影响[J].医学研究杂志,2017,46(9):134-138 |
| DOI：
10.11969/j.issn.1673-548X.2017.09.035 |
| 摘要点击次数: 823 |
| 全文下载次数: 708 |
|
|
| 中文摘要:目的 探讨胸腺五肽对新辅助化疗的乳腺癌组织微环境中浸润淋巴细胞的影响。方法 自2012年1月~2014年1月，前瞻性收集笔者医院收治的接受新辅助化疗的乳腺癌患者80例，将患者随机分为研究组和对照组，所有患者均行新辅助化疗，研究组在新辅助化疗期间给予胸腺五肽，化疗结束后进行手术切除肿瘤组织，留取乳腺癌组织标本，观察乳腺癌组织中和外周血中CD4+T细胞、CD8+T细胞、CD4+/CD8+T细胞比例、外周血中IL-6、IL-10、TGF-β1水平。结果 与对照组比较，研究组患者乳腺癌组织中CD4+T细胞显著降低（21.47%±3.29% vs 23.88%±3.43%，P=0.002）；CD8+T细胞显著增高（30.36%±4.38% vs 28.43%±4.16%，P=0.047）；CD4+/CD8+T细胞显著降低（0.71±0.14 vs 0.84±0.18，P=0.001）。两组患者治疗前外周血CD4+T细胞、CD4+/CD8+T细胞、IL-6、IL-10、TGF-β1等比较，差异均无统计学意义（P>0.05）。与对照组比较，研究组患者术后外周血CD4+T细胞水平显著增加（27.67%±4.24% vs 25.09%±3.68%，P=0.005）；CD4+/CD8+T显著增加（0.83±0.14 vs 0.75±0.18，P=0.029）；IL-6水平显著增高（12.39±2.87 vs 9.24±3.38ng/L，P=0.000）；IL-10水平显著降低（8.49±2.59 vs 12.59±3.65ng/L，P=0.006）；TGF-β1水平显著降低（12.47±3.88 vs 17.76±4.12ng/ml，P=0.000）。两组患者住院时间、切口感染、手术部位出血、复发率和病死率等比较，差异均无统计学意义（P > 0.05）。结论 胸腺五肽联合新辅助化疗可能有助于改善乳腺癌组织微环境中免疫状态和全身免疫功能。 |
| 中文关键词:乳腺癌 胸腺五肽 淋巴细胞浸润 新辅助化疗 |
| |
| Effect of Thymus Peptide Five on Infiltrating Lymphocytes in the Local Organization in Patients with Breast Cancer after Neoadjuvant Chemotherapy |
|
|
| Abstract:Objective To investigate the effect of thymus peptide five on infiltrating lymphocytes in the microenvironment of breast cancer with neoadjuvant chemotherapy. Methods From January 2012 to January 2014, 80 breast cancer patients received neoadjuvant chemotherapy admitted to our hospital were studied and were randomly assigned into a study group or a control group. All patients received neoadjuvant chemotherapy, while the study group received thymus peptide five during neoadjuvant chemotherapy.Surgical resection of tumor tissue were performed in all patients after neoadjuvant chemotherapy and tumor tissue were collected. The CD4+T cells, CD8+T cells, and the proportion of CD4+/CD8+T cells in peripheral blood and tumor tissue, the peripheral blood IL-6, IL-10 and TGF-β1 level were observed. Results When compared with the control group, CD4+T cells in the study group decreased significantly (21.47%±3.29% vs 23.88%±3.43%, P=0.002); CD8+ T cell increased apparently (30.36%±4.38% vs 28.43%±4.16%, P=0.047); and the proportion of CD4+/CD8+T cells decreased respectively (0.71±0.14 vs 0.84±0.18, P=0.001). There were no significant differences in peripheral blood CD4+T cells, CD4+/CD8+T cells, IL-6, IL-10, TGF-β1 between the two groups before treatment (P>0.05). When compared with the control group, patients in the study group got an elevated postoperative level of CD4+T cells in peripheral blood (27.67%±4.24% vs 25.09%±3.68%, P=0.005); a higher level of CD4+/CD8+T (0.83±0.14 vs 0.75±0.18, P=0.029); an increase in IL-6 level (12.39±2.87 vs 9.24±3.38ng/L, P=0.000); a decrease in IL-10 (8.49±2.59 vs 12.59±3.65ng/L, P=0.006); and a decrease in TGF-β1 (12.47±3.88 vs 17.76±4.12ng/ml, P=0.000). There were no significant differences between the two groups in hospital duration, incision infection, surgical site bleeding, recurrence rate and mortality (P>0.05). Conclusion Thymus peptide five combined with neoadjuvant chemotherapy might be helpful to improve the immune status in the microenvironment and the total immune function in patients with breast cancer. |
| keywords:Breast cancer Thymus peptide five Lymphocyte infiltration Neoadjuvant chemotherapy |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
